Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma

MLA

Kaori Kuramitsu, et al. “Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.” Anticancer Research, vol. 41, no. 9, July 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0ca4e0b7670c1d1eee2c688f61d36054&authtype=sso&custid=ns315887.

APA

Kaori Kuramitsu, Masahiro Kido, Hiroaki Yanagimoto, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Yuzo Kodama, Shinichi So, Shohei Komatsu, Hirochika Toyama, Takumi Fukumoto, & Yoshihiko Yano. (2021). Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma. Anticancer Research, 41(9).

Chicago

Kaori Kuramitsu, Masahiro Kido, Hiroaki Yanagimoto, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Yuzo Kodama, et al. 2021. “Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.” Anticancer Research 41 (9). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....0ca4e0b7670c1d1eee2c688f61d36054&authtype=sso&custid=ns315887.